{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:45:23Z","timestamp":1794775523683,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Spine J"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pyogenic spondylodiscitis and vertebral osteomyelitis remain challenging clinical entities, particularly when surgical intervention is required. While recombinant human bone morphogenetic protein-2 (rhBMP-2) is well established in degenerative spinal fusion, its role in the context of active or previously treated spinal infection remains controversial. This focused review evaluates the clinical outcomes, safety profile, and cost considerations of rhBMP-2 in the surgical management of pyogenic spondylodiscitis and vertebral osteomyelitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A focused literature review was conducted to identify studies reporting on the use of rhBMP-2 in patients undergoing spinal fusion for pyogenic spondylodiscitis and vertebral osteomyelitis. Data were extracted on patient demographics, rhBMP-2 dose, fusion rates, complication profiles, infection recurrence, neurological outcomes, and cost-related metrics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Six retrospective studies encompassing 346 patients treated with rhBMP-2 were included. Fusion rates ranged from 95 to 100%, with a weighted average of 97.84% across reported studies. Infection recurrence was low at 1.54%, and no study attributed reinfection to rhBMP-2 use. The complication rate averaged 18.49%, with only one transient rhBMP-2 related event (radiculitis) reported. Neurological improvement was observed in 68.0% of patients. Cost data, though limited, suggest reduced long-term healthcare utilisation in rhBMP-2 treated patients, potentially offsetting initial implant costs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Based on currently available retrospective data, rhBMP-2 appears to be a potentially safe adjunct in the surgical management of pyogenic spondylodiscitis and vertebral osteomyelitis. When used selectively, it has been associated with high fusion rates and an acceptable safety profile. These findings support the need for prospective, controlled trials to further define its optimal role, dosing strategies, and cost-effectiveness in the surgical management of pyogenic spondylodiscitis and vertebral osteomyelitis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00586-025-08993-9","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T10:38:39Z","timestamp":1749724719000},"page":"4631-4637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcomes, safety, and cost considerations of rhBMP-2 in the surgical management of pyogenic spinal infections: a focused review"],"prefix":"10.1007","volume":"34","author":[{"given":"Hassan","family":"Mahfouz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaid","family":"Al Farii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"issue":"1","key":"8993_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3171\/spi.2007.6.1.23","volume":"6","author":"HE Aryan","year":"2007","unstructured":"Aryan HE, Lu DC, Acosta FL Jr, Ames CP (2007) Corpectomy followed by the placement of instrumentation with titanium cages and Recombinant human bone morphogenetic protein\u20132 for vertebral osteomyelitis. J Neurosurg Spine 6(1):23\u201330. https:\/\/doi.org\/10.3171\/spi.2007.6.1.23","journal-title":"J Neurosurg Spine"},{"key":"8993_CR2","doi-asserted-by":"publisher","unstructured":"Medina AV, Murray Ortiz G, Estronza Ojeda S, Garc\u00eda Alvarez A, Espinosa Y (2024) Use of Recombinant human bone morphogenetic Protein-2 after anterior cervical corpectomy and fusion for the treatment of vertebral osteomyelitis. World Neurosurg 187\u2013e34. https:\/\/doi.org\/10.1016\/j.wneu.2024.03.047","DOI":"10.1016\/j.wneu.2024.03.047"},{"key":"8993_CR3","doi-asserted-by":"publisher","unstructured":"Issa K, Diebo BG, Faloon M, Naziri Q, Pourtaheri S, Paulino CB et al (2018) The epidemiology of vertebral osteomyelitis in the united States from 1998 to 2013. Clin Spine Surg 31(2). https:\/\/doi.org\/10.1097\/bsd.0000000000000597","DOI":"10.1097\/bsd.0000000000000597"},{"issue":"4","key":"8993_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jinf.2013.11.011","volume":"68","author":"M Kehrer","year":"2014","unstructured":"Kehrer M, Pedersen C, Jensen TG, Lassen AT (2014) Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study. J Infect 68(4):313\u2013320. https:\/\/doi.org\/10.1016\/j.jinf.2013.11.011","journal-title":"J Infect"},{"key":"8993_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41394-018-0099-y","volume":"4","author":"M Brummerstedt","year":"2018","unstructured":"Brummerstedt M, Bangstrup M, Barfod TS (2018) High mortality from pyogenic vertebral osteomyelitis: a retrospective cohort study. Spinal Cord Ser Cases 4:59.  https:\/\/doi.org\/10.1038\/s41394-018-0099-y","journal-title":"Spinal Cord Ser Cases"},{"issue":"26","key":"8993_CR6","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1097\/brs.0b013e31815cde3e","volume":"32","author":"RT Allen","year":"2007","unstructured":"Allen RT, Lee YP, Stimson E, Garfin SR (2007) Bone morphogenetic protein-2 (BMP-2) in the treatment of pyogenic vertebral osteomyelitis. Spine (Phila Pa 1976) 32(26):2996\u20133006.  https:\/\/doi.org\/10.1097\/brs.0b013e31815cde3e","journal-title":"Spine (Phila Pa 1976)"},{"issue":"3","key":"8993_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00586-015-4318-y","volume":"25","author":"JP Rutges","year":"2016","unstructured":"Rutges JP, Kempen DH, van Dijk M, Oner FC (2016) Outcome of Conservative and surgical treatment of pyogenic spondylodiscitis: a systematic literature review. Eur Spine J 25(3):983\u2013999. https:\/\/doi.org\/10.1007\/s00586-015-4318-y","journal-title":"Eur Spine J"},{"key":"8993_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jocn.2021.11.018","volume":"95","author":"LY Yaw Tee","year":"2022","unstructured":"Yaw Tee LY, Hunter S, Baker JF (2022) BMP use in the surgical treatment of pyogenic spondylodiscitis: is it safe? J Clin Neurosci 95:94\u201398. https:\/\/doi.org\/10.1016\/j.jocn.2021.11.018","journal-title":"J Clin Neurosci"},{"key":"8993_CR9","doi-asserted-by":"publisher","unstructured":"Shields LBE (2006) MD*; Raque, George H. MD*; Glassman, Steven D. MD\u2020; Campbell, Mitchell MD\u2020; Vitaz, Todd MD*; Harpring, John MD*; Shields, Christopher B. MD*. Adverse Effects Associated With High-Dose Recombinant Human Bone Morphogenetic Protein-2 Use in Anterior Cervical Spine Fusion. Spine 31(5):p 542\u2013547, March 1,| https:\/\/doi.org\/10.1097\/01.brs.0000201424.27509.72","DOI":"10.1097\/01.brs.0000201424.27509.72"},{"key":"8993_CR10","doi-asserted-by":"publisher","unstructured":"Mendenhall SK, Priddy BH, Mobasser JP, Potts EA (2021) Safety and efficacy of low-dose rhBMP-2 use for anterior cervical fusion. Neurosurg Focus.;50(6):E2. https:\/\/doi.org\/10.3171\/2021.3.FOCUS2171. PMID: 34062499","DOI":"10.3171\/2021.3.FOCUS2171"},{"issue":"5","key":"8993_CR11","doi-asserted-by":"publisher","first-page":"E139","DOI":"10.1097\/BRS.0b013e3181657ee3","volume":"33","author":"O\u2019Shaughnessy","year":"2008","unstructured":"O\u2019Shaughnessy BA, Kuklo TR, Ondra SL (2008) Surgical treatment of vertebral osteomyelitis with Recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 33(5):E139.  https:\/\/doi.org\/10.1097\/BRS.0b013e3181657ee3","journal-title":"Spine (Phila Pa 1976)"},{"key":"8993_CR12","doi-asserted-by":"publisher","unstructured":"Sharma, M., Dietz, N., Alhourani, A., Ugiliweneza, B., Wang, D., Drazin, D., & Boakye, M. (2019). Insights into complication rates, reoperation rates, and healthcare utilization associated with use of recombinant human bone morphogenetic protein-2 in patients with spine infections. Neurosurgical Focus, 46(1), E8. https:\/\/doi.org\/10.3171\/2018.10.FOCUS18448","DOI":"10.3171\/2018.10.FOCUS18448"},{"issue":"4","key":"8993_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1179\/2047480615Z.000000000329","volume":"24","author":"R Ferrari","year":"2015","unstructured":"Ferrari R (2015) Writing narrative style literature reviews. Med Writ 24(4):230\u2013235. https:\/\/doi.org\/10.1179\/2047480615Z.000000000329","journal-title":"Med Writ"},{"issue":"3","key":"8993_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00005131-198909000-00002","volume":"3","author":"EM Younger","year":"1989","unstructured":"Younger EM, Chapman MW (1989) Morbidity at bone graft donor sites. J Orthop Trauma 3(3):192\u2013195 https:\/\/doi.org\/10.1097\/00005131-198909000-00002","journal-title":"J Orthop Trauma"},{"issue":"6","key":"8993_CR15","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00586-019-06257-x","volume":"29","author":"JT Feng","year":"2020","unstructured":"Feng JT, Yang XG, Wang F, He X, Hu YC (2020) Efficacy and safety of bone substitutes in lumbar spinal fusion: a systematic review and network meta-analysis of randomized controlled trials. Eur Spine J 29(6):1261\u20131276. https:\/\/doi.org\/10.1007\/s00586-019-06257-x","journal-title":"Eur Spine J"},{"issue":"9 Suppl","key":"8993_CR16","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1097\/BRS.0b013e3181d81ef2","volume":"35","author":"TE Mroz","year":"2010","unstructured":"Mroz TE, Wang JC, Hashimoto R, Norvell DC (2010) Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 35(9 Suppl):S86\u2013104Mroz TE, Wang JC, Hashimoto R, Norvell DC (2010) Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 35(9 Suppl):S86\u2013104 https:\/\/doi.org\/10.1097\/BRS.0b013e3181d81ef2","journal-title":"Spine (Phila Pa 1976)"},{"issue":"6","key":"8993_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.spinee.2011.04.023","volume":"11","author":"EJ Carragee","year":"2011","unstructured":"Carragee EJ, Hurwitz EL, Weiner BK (2011) A critical review of Recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11(6):471\u2013491https:\/\/doi.org\/10.1016\/j.spinee.2011.04.023 https:\/\/doi.org\/10.1016\/j.spinee.2011.04.023","journal-title":"Spine J"},{"issue":"6","key":"8993_CR18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00586-009-0935-7","volume":"18","author":"V Alt","year":"2009","unstructured":"Alt V, Chhabra A, Franke J, Cuche M, Schnettler R, Le Huec JC (2009) An economic analysis of using rhBMP-2 for lumbar fusion in Germany, France and the UK from a societal perspective. Eur Spine J 18(6):800\u2013806. https:\/\/doi.org\/10.1007\/s00586-009-0935-7","journal-title":"Eur Spine J"},{"issue":"2","key":"8993_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/21925682241310864","volume":"14","author":"MD Daubs","year":"2024","unstructured":"Nunna, R. S., Gruber, M. D., Karuparti, S., Taylor, Z., Genovese, S., Jumah, F.,... & Chapman, J. R. (2025). Cost-Effectiveness Analyses of Bone Morphogenetic Protein 2 (rhBMP-2) in Spinal Fusion: A Systematic Review. Global Spine Journal, 15(4), 2514-2535. https:\/\/doi.org\/10.1177\/21925682241310864","journal-title":"Global Spine J"}],"container-title":["European Spine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00586-025-08993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00586-025-08993-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00586-025-08993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T10:07:53Z","timestamp":1759572473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00586-025-08993-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["8993"],"URL":"https:\/\/doi.org\/10.1007\/s00586-025-08993-9","relation":{},"ISSN":["0940-6719","1432-0932"],"issn-type":[{"value":"0940-6719","type":"print"},{"value":"1432-0932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}